title: Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging.
abstract: The efficacy resulting from adjunctive use of supraphysiological doses of levothyroxine has emerged as a promising approach to therapy and prophylaxis for refractory mood disorders. Most patients with mood disorders who receive treatment with supraphysiological doses of levothyroxine have normal peripheral thyroid hormone levels, and also respond differently to the hormone and tolerate it better than healthy individuals and patients with primary thyroid diseases. Progress in molecular and functional brain imaging techniques has provided a new understanding of these phenomena, illuminating the relationship between thyroid function, mood modulation and behavior. Thyroid hormones are widely distributed in the brain and have a multitude of effects on the central nervous system. Notably many of the limbic system structures where thyroid hormone receptors are prevalent have been implicated in the pathogenesis of mood disorders. The influence of the thyroid system on neurotransmitters (particularly serotonin and norepinephrine), which putatively play a major role in the regulation of mood and behavior, may contribute to the mechanisms of mood modulation. Recent functional brain imaging studies using positron emission tomography (PET) with [ (18)F]-fluorodeoxyglucose demonstrated that thyroid hormone treatment with levothyroxine affects regional brain metabolism in patients with hypothyroidism and bipolar disorder. Theses studies confirm that thyroid hormones are active in modulating metabolic function in the mature adult brain, and provide intriging neuroanatomic clues that may guide future research.
authors.affiliation: Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Charité-Mitte (CCM), Berlin, Germany. michael.bauer@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Bauer
authors.forename: E D
authors.initials: ED
authors.lastname: London
authors.forename: D H
authors.initials: DH
authors.lastname: Silverman
authors.forename: N
authors.initials: N
authors.lastname: Rasgon
authors.forename: J
authors.initials: J
authors.lastname: Kirchheiner
authors.forename: P C
authors.initials: PC
authors.lastname: Whybrow
mesh_terms: D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy; D001921:Brain / Q000378:metabolism*; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy; D008032:Limbic System / Q000378:metabolism; D019964:Mood Disorders / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D013959:Thyroid Diseases / Q000150:complications* / Q000235:genetics / Q000378:metabolism; D013961:Thyroid Gland / Q000503:physiopathology; D013963:Thyroid Hormones / Q000378:metabolism / Q000627:therapeutic use*; D013974:Thyroxine / Q000627:therapeutic use; D014055:Tomography, Emission-Computed
chemical_list: D013963:Thyroid Hormones; D012701:Serotonin; D013974:Thyroxine; D009638:Norepinephrine